Tse, Archie
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers on CoChat
Most cited papers
- Verified
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 1,081
- Verified
Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
Harrington, K. J., Brody, J., Ingham, M., Strauss, J., Cemerski, S., Wang, M., Tse, A., Khilnani, A., Marabelle, A., & Golan, T. (2018) · Annals of Oncology
interferon and immune responsesCancer Immunotherapy and Biomarkers
Cited by 280
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free